Bi- and multispecific antibodies and combination therapy remain one of the most important and central areas of antibody engineering. Innovative platforms and engineering approaches have created the next generation of multispecific antibodies with novel functionalities and features. This conference will highlight efforts to identify attributes early in the process to make necessary improvements to constructs and avoid failures in the clinic late in the development process. Join the leading faculty in this field as we explore one of the most exciting areas in biologics and discover what the newest platforms and engineering approaches are that promise an increasingly diverse array of new constructs and strategies that can achieve unprecedented efficacy.

For more details on the conference, please contact:

Christina Lingham
Executive Director, Conferences and Fellow
Cambridge Healthtech Institute
Phone: (+1) 508-813-7570
Email: clingham@healthtech.com

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5452
Email: jgerardi@healthtech.com

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1340
Email: ashleyparsons@healthtech.com

Conference Programs

• Display of Biologics
• Engineering Antibodies
• Machine Learning: Part 2

• Antibody-Based Therapies
• Emerging Targets & Approaches
• Membrane Protein Targets

• Safety & Efficacy
• Advancing Multispecifics
• Engineering Bispecifics

• Modulating the TME
• Innovative CAR T Therapy
• Next-Gen Immunotherapies

• Optimisation & Developability
• Analytical Characterisation
• Protein Stability & Formulation

• Data Science & Engineering
• Optimising Expression
• Process Development

• Intro to Machine Learning
• Machine Learning: Part 1
• Machine Learning: Part 2

• Antibody-Based Therapies
• Engineering Conjugates
• Next-Gen Immunotherapies

---